ARTICLE | Management Tracks
AbbVie’s Severino joins Flagship’s Tessera as CEO
Plus new CFO, CMO at Renibus, and updates from Bayer, Gilead, Shionogi and more
June 3, 2022 12:54 AM UTC
Weeks after Tessera Therapeutics Inc. closed a series C round with roughly $300 million, former AbbVie Inc. (NYSE:ABBV) vice chairman and president Michael Severino has joined the Flagship Pioneering-backed genetic medicines company as CEO. Severino will also be a CEO-Partner at Flagship.
During his eight years at AbbVie, Severino also held the titles of EVP of R&D and CSO. He previously held several roles at Amgen Inc. (NASDAQ:AMGN) spanning nearly 10 years...